{
    "nctId": "NCT01050075",
    "briefTitle": "Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel",
    "officialTitle": "A Pilot Study Investigating the Feasibility of Using Acupuncture for the Treatment of Taxane-Induced Peripheral Neuropathy",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 7,
    "primaryOutcomeMeasure": "Change in the Neuropathic Pain Symptom Inventory Scores",
    "eligibilityCriteria": "Inclusion\n\n* Patients must have a history of histologically or cytologically confirmed stage I, II, or III breast cancer that have received 2 cycles of paclitaxel, and expected to receive paclitaxel for two more cycles, and are experiencing grade 1 peripheral neuropathy (CTCAE criteria)\n* Performance ECOG 0-2 (Karnofsky Performance Status \\>= 60%)\n* Life expectancy of greater than 6 months\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion\n\n* Patients with radiologically confirmed stage IV breast cancer\n* Patients who had acupuncture in the previous 8 weeks\n* Change in use of any of the following drugs in the prior 4 weeks: opiates, antidepressants, or anxiolytics (\"change\" is defined as initiation or cessation of treatment, or change in prescribed dose or regimen)\n* Patients with needle phobia\n* Patients who experienced any peripheral neuropathy prior to chemotherapy\n* Patients who have the potential for serious bleeding due to inherited diseases such as hemophilia\n* Patients with diabetes",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}